ADMA Biologics Inc vs InMode Ltd — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while InMode Ltd trades at $15.22 (market cap $872.08M). The key difference: ADMA Biologics Inc is far larger — about 2.5× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | INMD | |
|---|---|---|
Market Cap | $2.22B | $872.08M |
Sector | Health | Technology |
52-Week High | $20.38 | $16.62 |
52-Week Low | $7.60 | $12.76 |
Enterprise Value | $2.29B | $375.42M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
InMode (INMD) trades at $15.17, down slightly by 0.13% today, with neutral technical signals and mixed earnings performance. The company maintains strong profitability with 76.52% gross margins and 20.69% net income margins, though Q1 2026 earnings missed expectations. Recent news highlights acquisition interest from Steel Partners at $16.75 per share and ongoing shareholder activism, creating both opportunity and uncertainty around corporate governance and valuation.
The stock presents a value opportunity with low P/E (12.52) and EV/EBITDA (5.37) multiples, but faces risks from earnings volatility, shareholder disputes, and potential undervaluation concerns. Analyst consensus leans neutral with 45% buy ratings, while technical indicators suggest range-bound trading near key support at $15. Investment appeal hinges on resolution of acquisition talks and sustained execution amid competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →